Clinical trial
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular…
NCT00092274 · GlaxoSmithKline, Industry · Withdrawn
Key facts
| NCT number | NCT00092274 |
|---|---|
| Title | Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma |
| Official title | An Open-label, International, Multicenter, Dose Escalating, Phase I/II Study of HuMax-CD20 in Patients With Relapsed or Refractory Follicular Lymphoma Grade I-II |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Follicular |
| Intervention type | Drug |
| Interventions | HuMax-CD20 |
| Enrollment | 0 |
| Start date | Sep 1, 2004 |
| Primary completion | Jan 1, 2005 |
| Completion | Jan 1, 2005 |
| First posted | Sep 27, 2004 |
| Last update posted | Apr 21, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: